[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digestive-system-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digestive-system-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100578889","phase-3-benefit-of-transcutaneous-auricular-vagus-nerve-stimulation-in-improving-quality-of-life-in-first-line-treatment-of-ovarian-cancer-100578889",false,"NCT06817161","Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:","Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial","ESTANVO","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* ECOG 0-2\n* Histologically proven epithelial ovarian carcinoma\n* FIGO stage ≥ IIB\n* Patient candidate for first line chemotherapy treatment (alone, neoadjuvant or adjuvant)\n* Patient affiliated to an appropriate social security system\n* Patient who has signed informed consent obtained before any trial related activities\n\nExclusion Criteria:\n\n* Patient with an active implantable medical device or any other implanted electronic or electrical device (pacemaker, defibrillator, etc.)\n* Dermatological problems in the area where stimulation electrodes are applied\n* Recent history (\\\u003C2 years) of epileptic seizures\n* Proven severe cardiovascular disease (such as known FEV \\\u003C40%, severe valvulpathy…) or HRV analysis not possible (such as uncontrolled atrial fibrillation)\n* Serious ear pathology\n* Documented vegetative neuropathy\n* Unusual morphology of the left ear which does not allow the use of the device\n* Patient with a cochlear implant near to the stimulation site\n* Impaired cognitive abilities\n* Concurrent other malignancy (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)\n* Pregnant or breastfeeding woman\n* Simultaneous participation in another clinical study that may compromise the conduct of this study.\n* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\n* Patient deprived of liberty or placed under the authority of a tutor","FEMALE","18 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS",[27,28,29],"Ovarian Carcinoma","First Line Chemotherapy","Digestive System Disorders",[31,32,33,34,35,36],"ovarian carinoma","parasympathetic","vagus nerve","transcutaneous auricular stimulation","quality of life","digestive symptoms","RECRUITING","2025-10-03",{"date":40,"type":41},"2025-10-07","ACTUAL",{"date":43,"type":41},"2025-04-30",{"date":45,"type":21},"2028-09-30",{"name":47,"class":48},"Centre Francois Baclesse","OTHER",4]